In a goal to bulk up its respiratory business, AstraZeneca has announced the acquisition of Actavis PLC’s branded respiratory drug business in the US and Canada.
Under the deal, the U.K. drug maker will be able to sell Actavis’s Tudorza Pressair and Daliresp—both chronic obstructive pulmonary disease drugs—in the U.S. and Canada. The products generated combined annual sales in the U.S. of around $230 million last year.
AstraZeneca will also own development rights for a therapy for the same condition in the U.S. The product is already approved in the European Union.
